Therapie der pulmonal arteriellen
Hypertonie (PAH)

H A Ghofrani; O Distler; F Gerhardt; M Gorenflo; E Grünig; W E Haefeli; M Held; M M Hoeper; C.-M Kähler; H Kaemmerer; H Klose; V Köllner; B Kopp; S Mebus; A Meyer; O Miera; D Pittrow; G Riemekasten; S Rosenkranz; D Schranz; R Voswinckel; H Olschewski

doi:10.1055/s-0030-1263316

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Dtsch Med Wochenschr 2010; 135: S87-S101
DOI: 10.1055/s-0030-1263316

Konsensus | Review article

Pneumologie, Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York

Therapie der pulmonal arteriellen Hypertonie (PAH)

Empfehlungen der Kölner Konsensus-Konferenz 2010Treatment of pulmonary arterial hypertension (PAH)Recommendations of the Cologne Consensus Conference 2010H. A. Ghofrani¹ , O. Distler² , F. Gerhardt³ , M. Gorenflo⁴ , E. Grünig⁵ , W. E. Haefeli⁶ , M. Held⁷ , M. M. Hoeper⁸ , C.-M Kähler⁹ , H. Kaemmerer¹⁰ , H. Klose¹¹ , V. Köllner¹² , B. Kopp¹³ , S. Mebus¹⁰ , A. Meyer¹⁴ , O. Miera¹⁵ , D. Pittrow¹⁶ , G. Riemekasten¹⁷ , S. Rosenkranz³ , D. Schranz¹⁸ , R. Voswinckel¹ , H. Olschewski¹⁹

¹Abteilung Pneumologie, Medizinische Klink II, Universitätsklinikum Gießen und Marburg, Standort Gießen
²Rheumaklinik, Universitätsspital Zürich, Schweiz
³Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln
⁴Department of Pediatric Cardiology, Leuven, Belgien
⁵Zentrum für pulmonale Hypertonie, Thoraxklinik am Universitätsklinikum Heidelberg
⁶Abt. Klinische Pharmakologie und Pharmakoepidemiologie, Universität Heidelberg
⁷ Missionsärztliche Klinik Würzburg
⁸Klinik für Pneumologie, Medizinische Hochschule Hannover
⁹Abt. Innere Medizin/Pneumologie, Universitätsklinikum Innsbruck
¹⁰ Klinik für Kinderkardiologie und angeborene Herzfehler, Deutsches Herzzentrum München
¹¹Abt. Pneumologie, Universitätsklinikum Hamburg-Eppendorf
¹²Fachklinik für Psychosomatische Medizin, MediClin Bliestal Kliniken, Blieskastel
¹³ Pulmonale Hypertonie e. V. (phev), Rheinstetten
¹⁴ Klinik für Pneumologie, Kliniken Maria Hilf, Mönchengladbach
¹⁵Abt. angeborene Herzfehler/Kinderkardiologie, Deutsches Herzzentrum, Berlin
¹⁶Institut für Klinische Pharmakologie, Medizinische Fakultät, Carl-Gustav Carus Technische Universität Dresden
¹⁷Medizinische Klinik, Abt. Rheumatologie, Charité Universitätsmedizin, Berlin
¹⁸ Kinderherzzentrum, Justus-Liebig-Universität Gießen
¹⁹ Abt. für Pneumologie, Universitätsklinikum Graz, Österreich

Further Information

Publication History

eingereicht: 5.8.2010

akzeptiert: 9.9.2010

Publication Date:
22 September 2010 (online)

Also available at

Abstract
Full Text
References

Permissions and Reprints

Zusammenfassung

Die 2009 veröffentlichen Europäischen Leitlinien zur Diagnostik und Therapie der pulmonalen Hypertonie sind nunmehr auch in Deutschland gültig. Die Leitlinien befassen sich eingehend mit der Therapie der pulmonal arteriellen Hypertonie (PAH). Für die praktische Umsetzung der Europäischen Leitlinien in Deutschland sind jedoch zahlreiche für Deutschland spezifische Gesichtspunkte und bereits wieder neue Daten bedeutsam, die eine ausführliche Kommentierung der Leitlinien und in einigen Punkten eine Aktualisierung notwendig machen. Im Juni 2010 fand in Köln eine Konsensuskonferenz statt, die von den Arbeitsgruppe PH der Deutschen Gesellschaften für Kardiologie (DGK), Pneumologie (DGP) und Pädiatrische Kardiologie (DGPK) organisiert wurde. Die Konferenz befasste sich mit der Umsetzung der Europäischen Leitlinien in Deutschland. Dazu wurden verschiedene Arbeitsgruppen eingesetzt, von denen sich eine gezielt der Therapie der pulmonal arteriellen Hypertonie (PAH) widmete. Die Ergebnisse und Empfehlungen dieser Arbeitsgruppe werden in dem vorliegenden Manuskript detailliert beschrieben.

Abstract

The 2009 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension have been adopted for Germany. The guidelines contain detailed recommendations for the treatment of pulmonary arterial hypertension (PAH). However, the practical implementation of the European Guidelines in Germany requires the consideration of several country-specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update already appears necessary. In June 2010, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to the treatment of PAH. This commentary summarizes the results and recommendations of the working group on treatment of PAH.

Schlüsselwörter

Pulmonal arterielle Hypertonie (PAH) - Therapie - Prostanoide - Endothelin-Rezeptor-Antagonisten - Phosphodiesterase-5-Inhibitoren

Keywords

pulmonary arterial hypertension (PAH) - treatment - prostanoids - endothelin receptor antagonists - phosphodiesterase type 5 inhibitors

Literatur

1 Barst R J, Ivy D, Dingemanse J, Widlitz A. et al . Pharmacokinetics, safety and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003; 73 372-382

Google Scholar
2 Barst R J, Langleben D, Badesch D. et al . Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006; 47 2049-2056

Google Scholar
3 Barst R J, Langleben D, Frost A. et al . Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 169 441-447

Google Scholar
4 Barst R J, Rubin L J, Long W A. et al . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996; 334 296-302

Google Scholar
5 Beghetti M, Haworth S G, Bonnet D. et al . Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol. 2009; 68 948-955

Google Scholar
6 Bull T M, Fagan K A, Badesch D B. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am. 2005; 31 451-464, vi

Google Scholar
7 Carlsen J, Kjeldsen K, Gerstorft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS. 2002; 16 1568-1569

Google Scholar
8 Channick R N, Simonneau G, Sitbon O. et al . Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358 1119-1123

Google Scholar
9 Chau E M, Fan K Y, Chow W H. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007; 120 301-305

Google Scholar
10 Degano B, Yaici A, Le Pavec J. et al . Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J. 2009; 33 92-98

Google Scholar
11 De Man F S, Handoko M L, Groepenhoff H. et al . Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2009; 34 669-675

Google Scholar
12 Dimopoulos K, Inuzuka R, Goletto S. et al . Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010; 121 20-25

Google Scholar
13 Dupuis J, Hoeper M M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008; 31 407-414

Google Scholar
14 Evgenov O V, Pacher P, Schmidt P M. et al . NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006; 5 755-768

Google Scholar
15 Fernandes S M, Newburger J W, Lang P. et al . Usefullness of epoprostenol therapy in the severly ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003; 91 632-635

Google Scholar
16 Galie N, Beghetti M, Gatzoulis M A. et al . Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114 48-54

Google Scholar
17 Galie N, Brundage B H, Ghofrani H A. et al . Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119 2894-2903

Google Scholar
18 Galie N, Ghofrani H A, Torbicki A. et al . Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med. 2005; 353 2148-2157

Google Scholar
19 Galiè N, Hoeper M M, Humbert M. et al . Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30 2493-2537

Google Scholar
20 Galiè N, Hoeper M M, Humber M. et al . Guidelines for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J. 2009; 34 1219-1263

Google Scholar
21 Galie N, Manes A, Negro L. et al . A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009; 30 394-403

Google Scholar
22 Galie N, Olschewski H, Oudiz R J. et al . Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117 3010-3019

Google Scholar
23 Galie N, Rubin L, Hoeper M. et al . Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371 2093-2100

Google Scholar
24 Ghofrani H A, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur Respir Rev. 2009; 18 35-41

Google Scholar
25 Ghofrani H A, Hoeper M M, Halank M. et al . Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J. 2010a (in press);

Google Scholar
26 Ghofrani H A, Morrell N W, Hoeper M M. et al . Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010b ; DOI: 10.1164/rccm.201001–0123OC

Google Scholar
27 Grannas G, Neipp M, Hoeper M M. et al . Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases. Transplantation. 2008; 85 524-531

Google Scholar
28 Haworth S G, Hislop A A. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001 – 2006. Heart. 2009; 95 312-317

Google Scholar
29 Hoeper M M, Gall H, Seyfarth H J. et al . Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J. 2009; 34 132-137

Google Scholar
30 Hoeper M M, Ghofrani H A, Gorenflo M. et al . Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinien 2009. Pneumologie. 2010; 64 401-414

Google Scholar
31 Hoeper M M, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005; 26 858-863

Google Scholar
32 Hoeper M M, Seyfarth H J, Hoeffken G. et al . Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J. 2007; 30 1096-1102

Google Scholar
33 Krasuski R A, Hart S A, Smith B. et al . Association of anemia and long-term survival in patients with pulmonary hypertension. Int J Cardiol. 2010 (in press);

Google Scholar
34 Ladwig K H, Baumert J, Marten M. et al . Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results from the prospective living with an implanted cardioverter-defibrillator study. Arch Gen Psychiatry. 2008; 65 1324-1330

Google Scholar
35 McLaughlin V V, Benza R L, Rubin R J. et al . Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2010; 55 1915-1922

Google Scholar
36 McLaughlin V V, Oudiz R J, Frost A. et al . Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006; 174 1257-1263

Google Scholar
37 Mereles D, Ehlken N, Kreuscher S. et al . Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006; 114 1482-1489

Google Scholar
38 Moledina S, Hislop A A, Foster H, Schulze-Neick I, Haworth S G. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart. 2010; (Epub ahead of print)

Google Scholar
39 Mukerjee D, St G eorge D, Coleiro B. et al . Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003; 62 1088-1093

Google Scholar
40 Mukhopadhyay S, Sharma M, Ramakrishnan S. et al . Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation. 2006; 114 1807-1810

Google Scholar
41 Olschewski H, Gomberg-Maitland M. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008; 31 801-901

Google Scholar
42 Olschewski H, Simonneau G, Galie N. et al . Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347 322-329

Google Scholar
43 Oudiz R J, Galie N, Olschewski H. et al . Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54 1971-1981

Google Scholar
44 Perros F, Montani D, Dorfmüller P. et al . Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008; 178 81-88

Google Scholar
45 Reichenberger F, Voswinckel R, Steveling E. et al . Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006; 28 563-567

Google Scholar
46 Rosenzweig E B, Ivy D D, Wildlitz A. et al . Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005; 46 697-704

Google Scholar
47 Rubin L J, Badesch D B, Barst R J. et al . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346 896-903

Google Scholar
48 Schermuly R T, Dony E, Ghofrani H A. et al . Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005; 115 2811-2821

Google Scholar
49 Schumacher Y O, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS. 2001; 15 1747-1748

Google Scholar
50 Simonneau G, Barst R J, Galie N. et al . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165 800-804

Google Scholar
51 Simonneau G, Rubin L J, Galie N. et al . Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008; 149 521-530

Google Scholar
52 Sitbon O, Gressin V, Speich R. et al . Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 170 1212-1217

Google Scholar
53 Sitbon O, Humbert M, Jais X. et al . Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111 3105-3111

Google Scholar
54 Sitbon O, Lascoux-Combe C, Delfraissy J F. et al . Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008; 177 108-113

Google Scholar
55 Thamm M, Voswinckel R, Gall H. et al . Air travel is safe and well tolerated in clinically stable patients with stable pulmonary hypertension. ATS PH patients. Am J Respir Crit Care Med. 2009; 179 A3371 (Abstract)

Google Scholar
56 Tongers J, Schwerdtfeger B, Klein G. et al . Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J. 2007; 153 127-132

Google Scholar
57 Whooley M A, Simon G E. Managing depression in medical outpatients. N Engl J Med. 2000; 343 1942-1950

Google Scholar
58 Wilkins M R, Wharton J, Grimminger F, Ghofrani H A. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J. 2008; 32 198-209

Google Scholar

Prof. Dr. H. Ardeschir Ghofrani

Abteilung Pneumologie
Medizinische Klink II/IV
Universitätsklinikum Gießen und Marburg, Standort Gießen

Klinikstr. 36

35392 Gießen

Phone: 0641/99-42422

Fax: 0641/99-42419

Email: ardeschir.ghofrani@innere.med.uni-giessen.de

>